Atara Biotherapeutics, Inc. (ATRA) vs Humacyte, Inc. (HUMA)
A side-by-side comparison of Atara Biotherapeutics, Inc. and Humacyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATRA
Atara Biotherapeutics, Inc.
$9.40HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
HUMA
Humacyte, Inc.
$0.50HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ATRA vs HUMA
growth of $100 · dividends reinvested · last 6yATRA -98.4% (-49.7%/yr)HUMA -94.8% (-39.0%/yr)HUMA compounded faster over this window
ATRA HUMA
ATRA vs HUMA: by the numbers
- •ATRA is the larger company ($85M vs $84M market cap).
- •Both run net losses; ATRA's is the smaller (-269.42% vs -4560.82% net margin).
- •ATRA grew revenue faster over the past five years (56.10% vs 2.41% CAGR).
Metrics side by side
Valuation
| Metric | ATRA | HUMA |
|---|---|---|
| P/S ratio | 13.67 | 39.60 |
| P/B ratio | N/A | 2.69 |
Profitability
| Metric | ATRA | HUMA |
|---|---|---|
| Gross margin | 82.44% | -736.46% |
| Operating margin | 29.69% | -5271.69% |
| Net margin | -269.42% | -4560.82% |
| ROE | N/A | -309.44% |
| ROIC | -100.35% | -90.27% |
Growth (annualized)
| Metric | ATRA | HUMA |
|---|---|---|
| Revenue CAGR (5Y) | 56.10% | 2.41% |
| Total return CAGR (5Y) | -53.60% | -45.73% |
Frequently asked
- Which has grown faster, ATRA or HUMA?
- Over the past five years, ATRA grew revenue faster — ATRA at a 56.10% CAGR versus HUMA at 2.41%.
- How have ATRA and HUMA total returns compared?
- Over the past 5 years, ATRA delivered -53.60% and HUMA delivered -45.73% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Atara Biotherapeutics ROEHumacyte ROEAtara Biotherapeutics operating marginHumacyte operating marginAtara Biotherapeutics revenue growthHumacyte revenue growthAtara Biotherapeutics free cash flowHumacyte free cash flow
Atara Biotherapeutics & Humacyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.